Results 91 to 100 of about 4,026 (142)

Removal of the Active Pharmaceutical Substance Entecavir from Water via the Fenton Reaction or Action by the Cyanobacterium Microcystis novacekii

Toxics
Entecavir (ETV) is an antiviral used to treat chronic infection caused by the hepatitis B virus, which affects approximately 250 million people worldwide.
Cléssius Ribeiro de Souza, Gabriel Souza-Silva, Carolina Paula de Souza Moreira, Olívia Maria S. R. Vasconcelos, Kenia Pedrosa Nunes, Cíntia Aparecida J. Pereira, Marcos Paulo Gomes Mol, Micheline Rosa Silveira   +7 more
doaj   +1 more source

Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients

, 2017
Background & Aims: Oral antiviral therapy may reduce the disease progression of chronic hepatitis B (CHB) patients. We aimed to further investigate the efficacy of long-term entecavir therapy in reduction of the risk of hepatocellular carcinoma (HCC ...
Su, Tung-Hung;Hu, Tsung-Hui;Chen, Chi-Yi;Huang, Yi-Hsiang;Chuang, Wan-Long;Lin, Chun-Che;Wang, Chia-Chi;Su, Wei-Wen;Chen, Ming-Yao;Peng, Cheng-Yuan;Chien, Rong-Nan;Huang, Yi-Wen;Wang, Horng-Yuan;Lin, Chih-Lin;Yang, Sheng-Shun;Chen, Tsung-Ming;Mo, Lein-Ray;Hsu, Shih-Jer;Tseng, Kuo-Chih;Hsieh, Tsai-Yuan;Suk, Fat-Moon;Hu, Chi-Tan;Bair, Ming-Jong;Liang, Cheng-Chao;Lei, Yung-Chao;Tseng, Tai-Chung;Chen, Chi-Ling;Kao, Jia-Horng, 高嘉宏;蘇東弘;徐士哲;陳祈玲   +1 more
core   +1 more source

Entecavir-Associated Thrombocytopenia: A Case Report and Review of the Pathophysiology, Diagnosis, and Treatment of a Rare but Reversible Cause of Thrombocytopenia

Case Reports in Hematology, 2019
Drug-associated thrombocytopenia is often unrecognized. We report a 76-year-old female with lymphoma who presented with easy bruising and oral bleeding. She had undergone screening for hepatitis B virus (HBV) prior to starting rituximab and was found to ...
Binoy Yohannan, Dai Chu N. Luu, Mark Feldman   +2 more
doaj   +1 more source

Prospects for Controlling Hepatitis B Globally

Pathogens
Infection with the hepatitis B virus (HBV) is highly prevalent globally. Over 250 million people suffer from chronic hepatitis B, and more than 800,000 patients die each year due to hepatitis B complications, including liver cancer.
Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Fernando de Jesús, Octavio Corral, Carmen de Mendoza   +5 more
doaj   +1 more source

Is increasing the dose of Entecavir effective in partial virological responders?

, 2014
Ayse Erturk,1 Remzi Adnan Akdogan,2 Emine Parlak,3 Erkan Cure,2 Medine Cumhur Cure,4 Cinar Ozturk1 1Department of Infectious Diseases, 2Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey; 3Department of ...
Cure E, Adnan Akdogan R, Ozturk C, Erturk A, Parlak E, Cumhur Cure M   +5 more
core  

Demographic data of solid tumor patients undergoing systemic cytotoxic chemotherapy and using prophylactic entecavir or lamivudine.

, 2015
aEntecavir group included 6 head and neck cancers, 4 gynecologic cancers, and 7 genitourinary cancers. Lamivudine group included 31 head and neck cancers, 15 gynecologic cancers, and 11 genitourinary cancers.bSCC: systemic cytotoxic chemotherapycALT ...
Po-Hung Chiang (762840), Wei-Lun Tsai (563379), Jin-Shiung Cheng (563388), Hsueh-Wen Chang (415259), Feng-Woei Tsay (563385), Ping-I Hsu (563382), Kwok-Hung Lai (563380), Wen-Chi Chen (286343), Hsien-Chung Yu (563384), Hoi-Hung Chan (563383)   +9 more
core   +1 more source

Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

, 2015
Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first-line antivirals remains uncertain.
Dalekos, G. N., Raptopoulou-Gigi, M., Mimidis, K., Mela, M., Chouta, A., Ketikoglou, I., Hatzis, G., Papatheodoridis, G. V., Nikolopoulou, G., Manolakopoulos, S., Gogos, C., Manesis, E., Touloumi, G., HepNet Greece Study Grp, Karamanolis, D., Drakoulis, C., Ilias, A., Vafiadis-Zouboulis, I.   +17 more
core   +2 more sources

Experience of entecavir in renal graft recipients with chronic hepatitis B

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2011
Aim of investigation. To estimate efficacy and safety of entecavir (ETV) in chronic hepatitis B (CHB) at renal graft recipients (RGR).Material and methods.
M. L. Zubkin, Ye. P. Sel'kova, F. K. Kokoyeva, T. A. Semenenko, V. I. Chervinko, A. N. Kolomoyets, E. M. Balakirev, A. V. Frolov, T. P. Nekrasova   +8 more
doaj  

Serum miR-146a and miR-155 as Predictors of Virological Control After Entecavir Withdrawal in HBeAg-Positive Chronic Hepatitis B Patients

The Turkish Journal of Gastroenterology
Background/Aims: Distinct virological relapse (VR) has occurred after stopping the use of nucleos(t)ide analogues treatment in patients with chronic hepatitis B (CHB) who are positive for Hepatitis B e antigen (HBeAg).
Ming Li Xu, Li Huan Wang
doaj   +1 more source

Virological and biochemical responses following 48-week entecavir therapy.

, 2015
* Only detectable samples were included for calculation of the median.Virological and biochemical responses following 48-week entecavir therapy.
Yan-Yan Hua (688883), Ming Shi (78991), Wan-Li Sun (688882), Long Shi (331967), Bo Han (84102)   +4 more
core   +1 more source